

HSBC Global Funds ICAV (the "ICAV") 3 Dublin Landings North Wall Quay Dublin 1 Ireland

24 January 2024

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.

If you are in any doubt as to the action you should take you should seek advice from your investment consultant, tax adviser and/or legal adviser as appropriate.

If you have sold or transferred all of your shares in HSBC Global Funds ICAV (the "ICAV"), please pass this document at once to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee as soon as possible.

Unless otherwise defined herein, all capitalised terms used herein shall bear the same meaning as capitalised terms used in the prospectus for the ICAV dated 17 November 2023, as may be amended from time to time (the "Prospectus"). A copy of the Prospectus is available upon request during normal business hours from the ICAV or from the local representative of the ICAV in any jurisdiction in which the ICAV is registered for public distribution.

The Directors of the ICAV accept responsibility for the accuracy of the information contained in this document. To the best of the knowledge and belief of the Directors (who have taken all reasonable care to ensure that such is the case) the information contained in this document is in accordance with the facts and does not omit anything likely to affect the import of such information.

Please note that the Central Bank of Ireland (the "Central Bank") has not reviewed this letter.

Dear Shareholder,

Change in Dealing Deadline HSBC Global Funds ICAV – Global Sukuk UCITS ETF (the "Fund")

1. INTRODUCTION

The ICAV is an umbrella fund registered with and authorised by the Central Bank to carry on business, pursuant to Part 2 of the Irish Collective Asset-management Vehicles Act, 2015, as amended, and established as an undertaking for collective investment in transferable securities pursuant to the UCITS Regulations with segregated liability between its sub-funds (the "**Sub-Funds**").

2. CHANGE IN DEALING DEADLINE

The purpose of this letter is to notify you that, subject to the approval of the Central Bank, the ICAV proposes to issue an updated Supplement for the Fund (the "**Supplement**") in order to change the Dealing Deadline for the Fund from 2.00 pm (Irish time) on the Business Day prior to the relevant Dealing Day to 10.00 am on the relevant Dealing Day. The rationale for the change in the Dealing Deadline is to make this more convenient for Shareholders to place their trades in the Fund. The investment management process and typical timing of trades placed in the market will remain unchanged.

This will take effect from the date of noting of the Supplement by the Central Bank which is expected to occur in or around 9th February 2024 (the "Effective Date").

Registered in Ireland as an open-ended variable capital Irish collective asset-management vehicle and an umbrella fund with segregated liability between subfunds. Registration Number C173463. Registered Office as above. Directors: Peter Blessing, Eimear Cowhey, Feargal Dempsey, Anthony Jeffs (British), Simon Fryatt (British), Suzanne Williams (British)

3. ACTION TO BE TAKEN

You do not need to take any action in relation to this change in the Dealing Deadline unless you are investing in the Fund in which case you need to note the earlier deadline. However, if the change described in this letter does not suit your investment requirement, you may switch your shareholding to any other Sub-Fund within the ICAV range or redeem your investment free of charge.

Should you have any questions relating to these matters, you should either contact us at the above address or alternatively you should contact your stockbroker, bank manager, solicitor, accountant or other independent financial advisor.

Yours faithfully,

h lo ly

Director for and on behalf of HSBC Global Funds ICAV